Baxter Sheds Poorly Performing Blood Products Line For $540 Mil.
This article was originally published in The Gray Sheet
Executive SummaryBaxter will sell its blood collection and processing business to a pair of investment firms for $540 mil., it announced Oct. 3
You may also be interested in...
In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.